Drug-Eluting Stent

SAN FRANCISCO — A cobalt-chromium drug-eluting stent was noninferior to a stainless steel DES in patients with ACS who were undergoing PCI, according to 18-month results from the BIODEGRADE trial presented at TCT 2019.

SAN FRANCISCO — Among patients who underwent PCI for long lesions, IVUS-based guidance was associated with better outcomes than angiography-based guidance at 5 years, according to new data from the IVUS-XPL trial presented at TCT 2019.

As drug-eluting stent technology has evolved, stent thrombosis has become less of a risk and the standard recommendation of 1 year of dual antiplatelet therapy after PCI is being challenged, especially for patients at high bleeding risk.

Patients who underwent endovascular revascularization with a paclitaxel-based drug-eluting device did not have an increased mortality risk over an 11-year follow-up period, according to a safety analysis published in the European Heart Journal.

SAN FRANCISCO — Intravenous administration of a novel liposomal formulation of alendronate at the time of PCI with drug-eluting stents failed to reduce restenosis at 9 months in patients with diabetes enrolled in the BLADE-PCI trial.

SAN FRANCISCO — Final 5-year data from the EXCEL trial demonstrate similar rates of death, stroke or MI with PCI or CABG for treatment of patients with left main CAD, according to late-breaking data presented at TCT 2019.

In recognition of Peripheral Artery Disease Awareness Month in September, Healio has compiled a list of five recent updates on PAD.

SAN FRANCISCO — Among patients who underwent PCI with a bioresorbable polymer sirolimus-eluting stent, 3-month dual antiplatelet therapy was noninferior to longer DAPT, according to results from the MODEL U-SES study.

SAN FRANCISCO — In the first randomized trial to compare a durable-polymer DES with a polymer-free drug-coated stent in patients with high bleeding risk who received 1 month of dual antiplatelet therapy, treatment with the DES was as safe and effective as treatment with the DCS, according to results of the Onyx ONE trial presented at TCT 2019.

SAN FRANCISCO — Among patients who had PCI with a drug-eluting stent and were on dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy lowered bleeding risk without raising ischemic risk compared with continued DAPT, according to results of the TWILIGHT trial presented at TCT 2019.